Icariin Alleviates IL-1ß-Induced Matrix Degradation By Activating The Nrf2/ARE Pathway In Human Chondrocytes.
Drug Des Devel Ther
; 13: 3949-3961, 2019.
Article
en En
| MEDLINE
| ID: mdl-31819369
OBJECTIVE: Osteoarthritis (OA) is characterized by progressive matrix destruction of articular cartilage. This study aimed to investigate the potential antioxidative and chondroprotective effects and underlying mechanism of Icariin (ICA) in interleukin-1 beta (IL-1ß)-induced extracellular matrix (ECM) degradation of OA cartilage. METHODS: Human chondrocyte cell line HC-A was treated with different doses of ICA, and then MTT assay and PI staining were used to estimate ICA-induced chondrocyte apoptosis. Intracellular ROS and superoxide dismutase (SOD) and glutathione peroxidase (GPX) were measured after treatment by IL-1ß with or without ICA. The mRNA and protein expression levels of redox transcription factor Nrf2 and the downstream effector SOD-1, SOD-2, NQO-1 and HO-1 were assayed to explore the detailed mechanism by which ICA alleviates ECM degradation. Finally, to expound the role of Nrf2 in ICA-mediated chondroprotection, we specifically depleted Nrf2 in human chondrocytes and then pretreated them with ICA followed by IL-1ß. RESULTS: ICA had no cytotoxic effects on human chondrocytes and 10-9 M was selected as the optimum concentration. ROS induced by IL-1ß could drastically activate matrix-degrading proteases and ICA could significantly rescue the matrix degradation and excess ROS generation caused by IL-1ß. We observed that ICA activated the Nrf2/ARE pathway, consequently upregulating the generation of GPX and SOD. Ablation of Nrf2 abrogated the chondroprotective and antioxidative effects of ICA in IL-1ß-treated chondrocytes. CONCLUSION: ICA alleviates IL-1ß-induced matrix degradation and eliminates ROS by activating the Nrf2/ARE pathway.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Flavonoides
/
Medicamentos Herbarios Chinos
/
Condrocitos
/
Factor 2 Relacionado con NF-E2
/
Interleucina-1beta
/
Elementos de Respuesta Antioxidante
Límite:
Humans
Idioma:
En
Revista:
Drug Des Devel Ther
Asunto de la revista:
FARMACOLOGIA
/
TERAPIA POR MEDICAMENTOS
Año:
2019
Tipo del documento:
Article
Pais de publicación:
Nueva Zelanda